Tonix Pharmaceuticals Holding Corp. (TNXP)

Tonix Pharmaceuticals is currently enrolling participants in a Phase 3 trial for military-related posttraumatic stress disorder. For more information, please visit www.thehonorstudy.com or www.clinicaltrials.gov (NCT03062540).

Changing the Landscape

Tonix Pharmaceuticals is developing next-generation medicines to help important public health challenges.

Tonix's lead drug candidate was granted Breakthrough Therapy designation by the FDA for the treatment of posttraumatic stress disorder (PTSD).

Learn more

>8 Million Adults

Affected by Posttraumatic Stress Disorder (PTSD) ^Attribution

Latest News

Tonix Pharmaceuticals Presented New Data Related to Suicidal Ideation and Behaviors in Military-Related PTSD from the Phase 2 AtEase Study at the American Society of Clinical Psychopharmacology

• May 31, 2018 • 4:30 PM EDT

Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), presented data from the Phase 2 AtEase study of Tonmya®*…

Management Team

Our experienced team has a strong track record of success in drug approvals and value creation.

View Management

Clinical Pipeline

Tonix's lead product candidate, Tonmya, is being developed for the treatment of PTSD.

View Pipeline

About Tonix Pharmaceuticals

Tonix is developing innovative pharmaceutical products to address important public health challenges, with two programs focusing on posttraumatic stress disorder (PTSD). PTSD is a serious condition characterized by chronic disability, inadequate treatment options, and overall high utilization of healthcare services creating significant economic burden. Other development programs include TNX-801, a potential smallpox-preventing vaccine.